15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 存档 1 Genotype B and younger patient age associated with b ...
查看: 721|回复: 0

Genotype B and younger patient age associated with better response to low-dose [复制链接]

Rank: 9Rank: 9Rank: 9

现金
22902 元 
精华
16 
帖子
13768 
注册时间
2006-12-19 
最后登录
2019-7-12 

荣誉之星 心爱宝宝

1
发表于 2007-2-16 10:56
Genotype B and younger patient age associated with better response to
low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b
for hepatitis B e antigen-positive patients with chronic hepatitis B in
China.

Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka
Y, Mizokami M, Si CW.

Peking University First Hospital, Beijing 100034, China.

BACKGROUND: Cost and clinically significant adverse effects are the major
limiting factors of interferon (IFN) use in therapy for chronic hepatitis B
virus (HBV) infection. A clinical trial was conducted in China to study the
efficiency and clinical relevance of low-dose regimen of IFN treatment for
chronic HBV infection and to reveal factors predicting sustained combined
response. METHODS: During a randomized, open-label control study, hepatitis
B e antigen (HBeAg)-positive patients with chronic HBV infection (n=230)
were assigned to receive pegylated IFN- alpha -2b (1.0 micro g/kg) (n=115)
or IFN- alpha -2b (3 MIU; n=115) for a 24-week period. Sustained combined
response was assessed 24 weeks after the completion of treatment. RESULTS:
The greater rate of HBeAg loss in the pegylated IFN-group (23%) was the only
statistically significant difference between the 2 treatment arms observed
at the end of follow-up. The results of the multivariate statistical
analysis revealed that HBV genotype B and patient age (< or =25 years) were
2 independent factors associated with sustained combined response. A total
of 40% of patients with HBV genotype B aged < or =25-years achieved
sustained combined response. Only 4 (1.7%) of 230 patients discontinued
therapy because of clinically significant adverse effects. CONCLUSIONS: The
choice of low-dose IFN regimen might be a relevant clinical option to reduce
the cost and adverse effects of therapy for younger patients with chronic
HBV infection and genotype B infection in countries where it is prevalent.

PMID: 17243057 [PubMed - in process]
有时会治愈,常常去帮忙,总是去安慰 BEST WISHES
‹ 上一主题|下一主题

肝胆相照论坛

GMT+8, 2024-11-18 07:54 , Processed in 0.015618 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.